PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30898339-0	2019	Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.	Tolvaptan	55-64	arginine vasopressin	Homo sapiens	7-15	
30898339-6	2019	In tolvaptan-treated subjects, copeptin increased from baseline to week 3 (6.3 pmol/L versus 21.9 pmol/L, respectively).	Tolvaptan	3-12	arginine vasopressin	Homo sapiens	31-39	
30898339-7	2019	In tolvaptan-treated subjects with higher baseline copeptin levels, a larger treatment effect was noted with respect to kidney growth rate and eGFR decline.	Tolvaptan	3-12	arginine vasopressin	Homo sapiens	51-59	
30898339-8	2019	Tolvaptan-treated subjects with a larger percentage increase in copeptin from baseline to week 3 had a better disease outcome, with less kidney growth and eGFR decline after three years.	Tolvaptan	0-9	arginine vasopressin	Homo sapiens	64-72